UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 28

Sortiert nach

The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR-1 Antagonist, in Healthy Adult Subjects

Clinical pharmacology in drug development, 2013-10, Vol.2 (4), p.310-315

2013

Volltextzugriff (PDF)

Antihypertensive Response to Ketanserin: Influence of Race and Weight

Journal of clinical pharmacology, 1988-11, Vol.28 (11), p.1017-1022

1988

Volltextzugriff (PDF)

Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects

European journal of clinical pharmacology, 2011-05, Vol.67 (5), p.483-492

2011

Volltextzugriff (PDF)

Disposition of 14C-eptifibatide after intravenous administration to healthy men

Clinical therapeutics, 1998-03, Vol.20 (2), p.307-323

1998

Volltextzugriff (PDF)

The Effect of Antacid and Cimetidine on the Oral Absorption of the Antifungal Agent SCH 39304

Journal of clinical pharmacology, 1990-07, Vol.30 (7), p.638-642

1990

Volltextzugriff (PDF)

Effect of Food, Antacid, and Age on the Pharmacokinetics of the Oral Thrombin Receptor Antagonist Vorapaxar (SCH 530348) in Healthy Volunteers

Clinical pharmacology in drug development, 2013-07, Vol.2 (3), p.223-230

2013

Volltextzugriff (PDF)

Effect of Food on the Oral Bioavailability of Isosorbide-5-Mononitrate Administered as an Extended-Release Tablet

Journal of clinical pharmacology, 1995-02, Vol.35 (2), p.151-158

1995

Volltextzugriff (PDF)

The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar

Journal of clinical pharmacology, 2013-05, Vol.53 (5), p.540-549

2013

Volltextzugriff (PDF)

Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trial

Clinical pharmacology in drug development, 2014-01, Vol.3 (1), p.18-24

2014

Volltextzugriff (PDF)

Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects

Journal of clinical pharmacology, 2006-03, Vol.46 (3), p.321-327

2006

Volltextzugriff (PDF)

Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device

Clinical pharmacology in drug development, 2014-05, Vol.3 (3), p.222-228

2014

Volltextzugriff (PDF)

An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects

Clinical pharmacology in drug development, 2014-05, Vol.3 (3), p.229-234

2014

Volltextzugriff (PDF)

Ezetimibe : A review of its metabolism, pharmacokinetics and drug interactions

Clinical pharmacokinetics, 2005-01, Vol.44 (5), p.467-494

2005

Volltextzugriff (PDF)

Influence of Food on the Oral Bioavailability of Loratadine and Pseudoephedrine from Extended-Release Tablets in Healthy Volunteers

Journal of clinical pharmacology, 1996-10, Vol.36 (10), p.923-930

1996

Volltextzugriff (PDF)

The Influence of Multiple-Dose Vorapaxar, an Oral PAR-1 Receptor Antagonist, on the Single-Dose Pharmacokinetics and Pharmacodynamics of Digoxin

Clinical pharmacology in drug development, 2013-01, Vol.2 (1), p.90-98

2013

Volltextzugriff (PDF)

Interaction of Single-Dose Ezetimibe and Steady-State Cyclosporine in Renal Transplant Patients

Journal of clinical pharmacology, 2006-03, Vol.46 (3), p.328-336

2006

Volltextzugriff (PDF)

Mometasone furoate nasal spray : A review of safety and systemic effects

Drug safety, 2007-01, Vol.30 (4), p.317-326

2007

Volltextzugriff (PDF)

Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure

Clinical science (1979), 1996-09, Vol.91 (3), p.283

1996

Volltextzugriff (PDF)

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects

European journal of clinical pharmacology, 2012-03, Vol.68 (3), p.291-300

2012

Volltextzugriff (PDF)

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers

Clinical pharmacology in drug development, 2018-02, Vol.7 (2), p.143-150

2018

Volltextzugriff (PDF)

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

European journal of clinical pharmacology, 2012-03, Vol.68 (3), p.249-258

2012

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

European journal of clinical pharmacology, 2012-07, Vol.68 (7), p.1049-1056

2012

Volltextzugriff (PDF)

Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation

Clinical therapeutics, 1995-03, Vol.17 (2), p.241-251

1995

Volltextzugriff (PDF)

Pharmacokinetics of loratadine and pseudoephedrine following single and multiple doses of once- versus twice-daily combination tablet formulations in healthy adult males

Clinical therapeutics, 1997-09, Vol.19 (5), p.1002-1012

1997

Volltextzugriff (PDF)

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

European journal of clinical pharmacology, 2012-11, Vol.68 (11), p.1501-1508

2012

Volltextzugriff (PDF)

1 – 25 von 28

Suche als RSS-Feed

Aktive Filter

KollektionEZB Free E-Journals

KollektionPublisher or Other Site

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(28)

Sprache

Englisch
(28)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR-1 Antagonist, in Healthy Adult Subjects

Antihypertensive Response to Ketanserin: Influence of Race and Weight

Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects

Disposition of 14C-eptifibatide after intravenous administration to healthy men

The Effect of Antacid and Cimetidine on the Oral Absorption of the Antifungal Agent SCH 39304

Effect of Food, Antacid, and Age on the Pharmacokinetics of the Oral Thrombin Receptor Antagonist Vorapaxar (SCH 530348) in Healthy Volunteers

Effect of Food on the Oral Bioavailability of Isosorbide-5-Mononitrate Administered as an Extended-Release Tablet

The Effect of Multiple Doses of Ketoconazole or Rifampin on the Single- and Multiple-Dose Pharmacokinetics of Vorapaxar

Effect of the thrombin receptor antagonist (PAR-1) vorapaxar on QT/QTc interval in healthy volunteers: A randomized, placebo- and positive-controlled, parallel group trial

Effects of Ezetimibe on Cyclosporine Pharmacokinetics in Healthy Subjects

Evaluation of potential for pharmacokinetic interaction between mometasone furoate and formoterol fumarate after oral inhalation from a fixed-dose combination metered-dose inhaler device

An evaluation of the systemic bioavailability of mometasone furoate (MF) after oral inhalation from a MF/formoterol fumarate metered-dose inhaler versus an MF dry-powder inhaler in healthy subjects

Ezetimibe : A review of its metabolism, pharmacokinetics and drug interactions

Influence of Food on the Oral Bioavailability of Loratadine and Pseudoephedrine from Extended-Release Tablets in Healthy Volunteers

The Influence of Multiple-Dose Vorapaxar, an Oral PAR-1 Receptor Antagonist, on the Single-Dose Pharmacokinetics and Pharmacodynamics of Digoxin

Interaction of Single-Dose Ezetimibe and Steady-State Cyclosporine in Renal Transplant Patients

Mometasone furoate nasal spray : A review of safety and systemic effects

Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure

No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers

Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects

Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation

Pharmacokinetics of loratadine and pseudoephedrine following single and multiple doses of once- versus twice-daily combination tablet formulations in healthy adult males

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

Aktive Filter

Suchergebnisse filtern